Oncotelic Therapeutics, Inc. announced that it has entered into a securities purchase agreement pursuant to which company issued a convertible promissory note to returning investor Mast Hill Fund, L.P., a fund managed by Mast Hill Management, LLC for gross proceeds of $544,500 on May 27, 2022. The note is convertible into shares of the company's common stock, par value $0.01 per share. The principal amount of the note is $605,000.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0379 USD | -9.83% | -3.81% | -1.04% |
1st Jan change | Capi. | |
---|---|---|
-1.04% | 16.79M | |
-2.19% | 103B | |
+1.76% | 95.28B | |
+1.46% | 22.15B | |
-15.72% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.84% | 16.05B | |
+5.02% | 13.68B | |
+36.41% | 12.17B |
- Stock Market
- Equities
- OTLC Stock
- News Oncotelic Therapeutics, Inc.
- Oncotelic Therapeutics, Inc. announced that it has received $0.5445 million in funding from Mast Hill Management, LLC